Experienced in Acute Myeloblastic Leukemia without Maturation

Harry Dolstra

Nijmegen, GE, NL 
Experienced in Acute Myeloblastic Leukemia without Maturation
Nijmegen, GE, NL 
OverviewLocationsClinical Research

Overview

Harry Dolstra practices in Nijmegen, Netherlands. Mr. Dolstra is rated as an Experienced expert by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Familial Paroxysmal Nonkinesigenic Dyskinesia, Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 99 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Acute Myeloblastic Leukemia without Maturation.

Gender
Male

Locations

Nijmegen, GE, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug, Biological
Study Drug: Ex Vivo-Generated Natural Killer T Cells
Study Phase: Phase 1
Vaccination With PD-L1/L2-silenced Minor Histocompatibility Antigen-loaded Donor DC Vaccines to Boost Graft-versus-tumor Immunity After Allogeneic Stem Cell Transplantation (a Phase I/II Study)
Vaccination With PD-L1/L2-silenced Minor Histocompatibility Antigen-loaded Donor DC Vaccines to Boost Graft-versus-tumor Immunity After Allogeneic Stem Cell Transplantation (a Phase I/II Study)
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

99 Total Publications

IL-15 transpresentation by ovarian cancer cells improves CD34+ progenitor-derived NK cell's anti-tumor functionality.
IL-15 transpresentation by ovarian cancer cells improves CD34+ progenitor-derived NK cell's anti-tumor functionality.
Journal: Oncoimmunology
Published: February 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dolstra's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile